Navigation Links
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
Date:9/30/2013

SEATTLE, Sept. 30, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced that OMS824, its phosphodiesterase 10 (PDE10) inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia. As previously reported, Phase 1 clinical results in healthy subjects demonstrated that OMS824 is well tolerated and suggest that it has a better clinical therapeutic index or "safety factor" than other PDE10 inhibitors in development. Omeros plans to begin a Phase 2 clinical trial evaluating OMS824 in patients with Huntington's disease later this year. A Phase 2 clinical trial of the drug is already underway in patients with schizophrenia.

Orphan designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. It qualifies a company for benefits that apply across all stages of drug development, including accelerated approval process, seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and waiver of certain administrative fees.

Huntington's disease is estimated to affect approximately 31,000 U.S. patients annually, and the only FDA‑approved treatment for the disease is tetrabenazine, which is indicated for Huntington's-related movement disorders. OMS824 has the potential to improve the cognitive and psychiatric abnormalities as well as the movement disorders associated with the disease.

"Orphan designation by the FDA will help to acc
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
5. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
8. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
9. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
10. As Global Telemedicine Market Reaches $2.5 Billion, Industry Leaders Gather in San Diego to Discuss Grants, Funding, Vendor Selection, Credentialing, and More
11. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... OF PRUSSIA, Pa. , March 30, 2015 ... the European Medicines Agency (EMA) has started the ... Application (MAA) for its long-acting fusion protein linking ... Upon European Commission approval, rIX-FP will provide hemophilia ... well as the European Economic Area (EEA) countries, ...
(Date:3/30/2015)... , March 30, 2015  BioPharmX Corporation (OTCQB: ... development of novel drug delivery products to address ... today announced the appointment of Stephen Morlock ... veteran, to its board of directors.  Mr. Morlock,s ... to expand its national roll-out of Violet iodine, ...
(Date:3/30/2015)... 30, 2015 Beta-O2 ... as the company,s new chief executive officer. Dr. ... leading early stage Israeli venture capital firm. He is ... and vascular surgery.        (Logo: http://photos.prnewswire.com/prnh/20140910/705638) ... Sherpa Innoventures is Beta-O2,s newest investor, having participated in ...
Breaking Medicine Technology:European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients 2European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients 3European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients 4BioPharmX Corporation Appoints Stephen Morlock To Its Board Of Directors 2BioPharmX Corporation Appoints Stephen Morlock To Its Board Of Directors 3Beta-O2 Names Dr. Yuval Avni CEO 2Beta-O2 Names Dr. Yuval Avni CEO 3
... 5, 2011 Jennerex, Inc., a private clinical-stage ... of first-in-class targeted oncolytic products for cancer, and ... specialized in the development of immunotherapeutic products, today ... 2 clinical studies of JX-594 were presented in ...
... Pharmaceuticals, Inc. (NASDAQ: QCOR ) today announced preliminary ... The Company announced the preliminary metrics in advance of the ... Executive Officer of Questcor, will present on Tuesday, April 5, ... web cast of the presentation during or after the event, ...
Cached Medicine Technology:Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors 2Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors 3Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors 4Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors 5Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 2Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 3Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 4Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 5Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 6Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 7Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 8
(Date:3/30/2015)... 2015 According to a recently published ... repair market will continue to dominate the European soft ... due to increasing numbers of ventral hernias, and the ... “The significantly large market share represented by ventral hernia ... We’re seeing a growing use of expensive biologics,” explains ...
(Date:3/30/2015)... This report studies the global tumor ablation ... 2019. , Based on the type of technology, ... four major segments, namely radio-frequency, microwave, cryoablation and ... laser ablation) segments. Moreover, based on type of ... into three segments, namely, interventional radiology, surgery and ...
(Date:3/30/2015)... 2015 On March 19th, 2015, in ... of the Detroit Lions, LiveToBeSober.org hosted the “Fighting Addiction ... ministers and bishops as well as other civic leaders ... at the luncheon, including retired Detroit Lions wide receiver ... and two survivors of their own personal battles with ...
(Date:3/30/2015)... Pa. (PRWEB) March 30, 2015 ... the Halal certification for all current Epax® Ultra ... facility in Ålesund, Norway. The certification ensures the ... comply with the Islamic religious regulations for Halal. ... step in FMC’s efforts to further advance its ...
(Date:3/30/2015)... GenSight ®, provider of an Enterprise Portfolio ... The Forrester Wave™: Strategic Planning For The [Business Technology] ... positions GenSight as a leader and gave the company ... the analytics, corporate strategy, assessment, direction and life cycle ... the Leaders category. , According to the report: ...
Breaking Medicine News(10 mins):Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 3Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 2Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 3Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3
... that ravaged medieval Europe has a weakness that could help ... a study published on Thursday. ,A bacterium known ... Death spread when people are bitten by an infected flea, ... coughing or sneezing. ,There are periodic natural outbreaks ...
... comes to some of today’s health issues, 100 percent ... related to certain diseases – concludes// a study by ... ability to reduce risk compared to their whole fruit/vegetable ... conducted the literature review. The researchers analyzed a variety ...
... heavily on alternative therapists who mistreat their patients sexually ... therapists said to exist in Britain and there are ... On the other hand, completely qualified medical practitioners who ... rules and guidelines regarding their relationship with their patients. ...
... have a longer average lifespan than most of the men ... where it is usually reported// that people live longer on ... social policy study published on Wednesday, healthy Israeli men live ... than men, average lifespan of 82.4 years, on par with ...
... A US government funded study finds that CT scans used ... to be replaced by MRI scans which are better in ... should now be passed to magnetic resonance imaging,” wrote Dr. ... in Australia in a note accompanying the study report. ...
... presentation into Japanese for an American client who wants to ... not many can undertake. //And all this from Chennai too! ... proving that it is possible. Specialising in providing software services ... on the dot and raking in millions of dollars in ...
Cached Medicine News:Health News:Scientists Find Potential Weakness In Plague Germ 2Health News:Benefits of Fruit and Vegetable Juices 2Health News:Cashing in on IT for Healthcare 2
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic Economical Single use. Non-Sterile....
Medicine Products: